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Rickettsiae are obligate intracellular parasites of eukaryotic cells that are the
causative agents responsible for spotted fever and typhus. Their small genome
(about 800 protein-coding genes) is highly conserved across species and has
been postulated as the ancestor of the mitochondria. No genes that are required
for glycolysis are found in the Rickettsia prowazekii or mitochondrial genomes,
but a complete set of genes encoding components of the tricarboxylic acid cycle
and the respiratory-chain complex is found in both. A 2.4 A ˚ resolution crystal
structure of R. prowazekii fumarate hydratase, an enzyme catalyzing the third
step of the tricarboxylic acid cycle pathway that ultimately converts phospho-
enolpyruvate into succinyl-CoA, has been solved. A structure alignment with
human mitochondrial fumarate hydratase highlights the close similarity between
R. prowazekii and mitochondrial enzymes.
1. Introduction
Typhus epidemics have been recurrent in human history; the pattern
of infection was such that the bacterium Rickettsia prowazekii, the
agent of typhus, could arguably determine the outcome of war, with
outbreaks after World War I resulting in around three million deaths
(Raoult et al., 2004). Although hecatombs of this scale remain
exceptional, typhus continues to ravage populations in areas of
conﬂict, with mortality rates among infected patients of as high as
20% without antibiotics (Center for Biosecurity of UPMC; http://
upmc-biosecurity.org). Despite its biological characteristics (envir-
onmental stability, small size, aerosol transmission, persistence in
infected hosts, low infectious dose, high morbidity and substantial
mortality), R. prowazekii may not be a primary bioweapon candidate
because of its dependency on its eukaryotic host for propagation
(Azad, 2007), although this view remains disputed (Walker, 2009).
Nonetheless, the Center for Disease Control and Prevention (CDC)
ranks R. prowazekii as a Category B biological agent and the
Department of Health and Human Services (DHHS) classiﬁes it as a
top priority for the development of medical countermeasures, thus
further encouraging efforts to understand the mechanism of action of
this pathogen.
The complete genome of R. prowazekii contains only 834 protein-
coding genes, a very small number compared with the 5000 genes
found in the model bacterium Escherichia coli, highlighting simil-
arities between R. prowazekii and mitochondrial genes as well as the
absence of the genes required for anaerobic glycolysis. It has been
suggested that ATP production in Rickettsia is the same as that in
mitochondria (Andersson et al., 1998). Despite the difference in size
between the Rickettsia genome (over 1 000 000 bp) and that of
human mitochondrial DNA (16 000 bp), the results of phylogenetic
studies are consistent with an  -proteobacterial ancestry of the
mitochondrial genome (Gray et al., 2001). However, comparisons at
the protein level reveal a far more complex picture, since 90% of the
mitochondrial proteins are encoded in the nucleus (Gray et al., 2004).
One such example is fumarate hydratase, a mitochondrial enzyme
from the citric acid cycle, which is encoded on nuclear chromosome 1
in humans (Craig et al., 1976).
The tricarboxylic acid cycle (TCA; also known as the Krebs cycle
and the citric acid cycle) is a pathway that Tyler described in 1992 as‘so crucial to the metabolism of living cells that any signiﬁcant defect
is incompatible with life’ (Tyler, 1992). The cycle is constituted by a
series of biochemical reactions that lead to the progressive oxidative
decarboxylation of acetyl-CoA (see Fig. 1). The step that converts
fumarate to l-malate has recently been the target of studies of
tumorigenesis in humans (King et al., 2006) and pathogenicity in
bacteria (van Ooij, 2010).
Two classes of enzymes, class I and class II fumarate hydratase
(fumarase; FumC), reversibly convert fumarate to l-malate and
have no detectable sequence similarity (Woods et al., 1988). Class I
fumarases (FumA and FumB enzymes) are homodimeric, thermo-
labile, iron–sulfur-containing enzymes of approximately 120 kDa.
Class II fumarases (FumC enzymes) are homotetrameric, thermo-
stable, iron-independent enzymes with a molecular mass of 200 kDa.
The amino-acid sequences of mitochondrial class II FumCs are
highly conserved in eukaryotes and are most closely related to the
 -proteobacterial homologues (Schnarrenberger & Martin, 2002).
Defects in human FumC are the cause of fumarase deﬁciency, a
disease characterized by progressive encephalopathy, developmental
delay, hypotonia, cerebral atrophy and lactic and pyruvic acidemia
(Coughlin et al., 1998). Heterozygous germline mutations of FumC
were found in patients with multiple cutaneous and uterine leio-
myomas (MCUL). A further set of mutations is the cause of
hereditary leiomyomatosis and renal cell cancer (HLRCC). Research
to elucidate the mechanisms that lead to enhanced glycolysis in
tumours has shown that FumC and succinate dehydrogenase (SDH)
are tumour suppressors, demonstrating for the ﬁrst time how mito-
chondrial enzymes and their dysfunction are associated with tumori-
genesis (King et al., 2006). A dedicated online database of FumC gene
mutations lists all reported FumC sequence variants (Bayley et al.,
2008).
Besides its involvement in human tumorigenesis, the TCA cycle
has been targeted for its role in pathogenicity. In particular, FumC
was found to be one of nine in vivo-induced virulence factors in
Listeria (Wilson et al., 2001) and to bind PdhS, an essential cyto-
plasmic histidine kinase involved in differentiation, in Brucella
(Mignolet et al., 2010). A recent paper further shows that the TCA
cycle signals the switch between a pathogenic state and a mutualistic
state when the Photorhabdus bacterium changes hosts (Lango &
Clarke, 2010).
To this day, the SSGCID project is the sole depositor of Rickettsia
structures in the Protein Data Bank. Here, we present the high-
resolution structure of R. prowazekii FumC and compare it with that
of its human mitochondrial homolog.
2. Methods
2.1. Protein expression and purification
FumC from R. prowazekii strain Madrid E (NCBI NP_221027;
fumC gene; EC 4.2.1.2; UniProt Q9ZCQ4) spanning the full-length
protein from residues 1–461 (‘ORF’) was cloned into the ligation-
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Figure 1
Chemical reaction pathway of the tricarboxylic acid cycle (TCA; also known as the Krebs cycle and the citric acid cycle); catalytic enzymes are indicated in pink boxes, with
fumarase, the subject of this study, highlighted in red. This ﬁgure was prepared with CellDesigner (Funahashi et al., 2003).independent cloning (LIC; Aslanidis & de Jong, 1990) expression
vector pAVA0421 encoding an N-terminal hexahistidine afﬁnity tag
followed by the human rhinovirus 3C protease cleavage sequence
(MAHHHHHHMGTLEAQTQGPGS-ORF).
The construct encoding the gene for FumC was transformed into
chemically competent E. coli BL21 (DE3) Rosetta cells. An overnight
culture was grown in LB broth at 310 K and was used to inoculate 2 l
ZYP-5052 auto-induction medium, which was prepared as described
by Studier (2005). FumC was expressed in a LEX bioreactor in the
presence of antibiotics. After 24 h at 298 K, the temperature was
reduced to 288 K for a further 60 h. The sample was centrifuged at
4000g for 20 min at 277 K and the cell paste was ﬂash-frozen in liquid
nitrogen and stored at 193 K.
During the puriﬁcation process, the frozen cell pellet was thawed
and completely resuspended in lysis buffer (20 mM HEPES pH 7.4,
300 mM NaCl, 5% glycerol, 30 mM imidazole, 0.5% CHAPS, 10 mM
MgCl2,3 m M  -mercaptoethanol, 1.3 mg ml
 1 protease-inhibitor
cocktail and 0.05 mg ml
 1 lysozyme). The resuspended cell pellet was
then disrupted on ice for 15 min with a Branson Digital 450D Soniﬁer
(70% amplitude, with alternating cycles of 5 s pulse-on and 10 s
pulse-off). The cell debris was incubated with 20 ml Benzonase
nuclease at room temperature for 40 min. The lysate was clariﬁed by
centrifugation with a Sorvall RC5 at 10 000 rev min
 1 for 60 min at
277 K in a F14S Rotor (Thermo Fisher). The clariﬁed solution was
syringe-ﬁltered through a 0.45 mm cellulose acetate ﬁlter (Corning
Life Sciences, Lowell, Massachusetts, USA). The lysate was puriﬁed
by IMAC using a HisTrap FF 5 ml column (GE Biosciences, Piscat-
away, New Jersey, USA) equilibrated with binding buffer (25 mM
HEPES pH 7.0, 300 mM NaCl, 5% glycerol, 30 mM imidazole, 1 mM
TCEP) and eluted with 500 mM imidazole in the same buffer. The
eluted FumC was concentrated and further resolved by size-exclusion
chromatography (SEC) using a Superdex 75 26/60 column (GE
Biosciences) equilibrated in SEC buffer (20 mM HEPES pH 7.0,
300 mM NaCl, 5% glycerol and 1 mM TCEP) attached to an A ¨ KTA
FPLC system (GE Biosciences). Peak fractions were collected and
pooled based on purity-proﬁle assessment by SDS–PAGE. Concen-
trated pure protein was ﬂash-frozen in liquid nitrogen and stored at
193 K. The ﬁnal concentration (39.5 mg ml
 1) was determined by UV
spectrophotometry at 280 nm using a molar extinction coefﬁcient of
33 015 M
 1 cm
 1 and the ﬁnal purity (>97%) was assayed by SDS–
PAGE.
2.2. Crystallization
Crystallization trials were set up according to a rational crystal-
lization approach (Newman et al., 2005) using the JCSG+ and PACT
sparse-matrix screens from Emerald BioSystems and Molecular
Dimensions. Protein (39.5 mg ml
 1,0 . 4 ml) in SEC buffer (20 mM
HEPES pH 7.0, 300 mM NaCl, 5% glycerol and 1 mM TCEP) was
mixed with an equal volume of precipitant and equilibrated against
an 80 ml reservoir in sitting-drop vapor-diffusion format in 96-well
Compact Jr plates from Emerald BioSystems at 289 K. Within six
weeks, crystals grew in the presence of 2.4 M sodium malonate
(JCSG+ condition F9). A gradient optimization screen was designed
based on this condition and crystals grew from this screen after about
six weeks in 1.4 M sodium malonate pH 6.0.
2.3. Data collection and structure determination
A crystal was harvested, cryoprotected with a solution consisting of
the precipitant supplemented with 20% glycerol and vitriﬁed in liquid
nitrogen. A 2.4 A ˚ resolution data set was collected at the Advanced
Light Source (Andersson et al., 1998) onbeamline 5.0.2 (Table 1). The
data were reduced with XDS/XSCALE (Kabsch, 2010). The structure
was determined by molecular replacement using human FumC (PDB
entry 3e04; Structural Genomics Consortium, unpublished work) as a
search model in Phaser (McCoy et al., 2007) from the CCP4 suite
(Winn et al., 2011). The reﬁnement statistics are shown in Table 2. The
asymmetric unit contained two protomers of the biologically relevant
tetramer, with the other two protomers being generated by crystal-
lographic symmetry. The ﬁnal model was obtained after numerous
iterative rounds of reﬁnement in REFMAC (Murshudov et al., 2011)
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Figure 2
Ribbon diagram of the homodimeric unit structure of R. prowazekii FumC showing
(a) the overall fold gradient-coloured from red (N-terminus) to blue (C-terminus)
and (b) the backbone trace of chain A (blue) and chain B (brown) of the dimeric
unit. This ﬁgure and all other structure ﬁgures in this paper (except for Fig. 5) were
prepared using the POV-Ray renderer (http://povray.org) and DeepView (Guex &
Peitsch, 1997).and manual rebuilding in Coot (Emsley & Cowtan, 2004). The ﬁnal
model consisted of residues Asn3–Glu457 with no internal gaps
for protomer A, residues Asn3–Pro316 and Met321–Leu406 for
protomer B, 198 water molecules, two malonate molecules (one
bound to each protomer) and a sodium ion assigned based on the
crystallization conditions (sodium malonate), B factors and coordi-
nation distances of  2.5 A ˚ (Zheng et al., 2008). The structure was
assessed and corrected for geometry and ﬁtness using MolProbity
(Chen et al., 2010).
3. Discussion
The R. prowazekii FumC structure was determined in complex with
the product analog malonate. Like the ﬁrst reported FumC structure
from E. coli (Weaver et al., 1995), R. prowazekii FumC crystallized
as a homodimer containing two subunits of the normally tetrameric
enzyme (see Fig. 2), in which each chain forms an elongated central
four-helix bundle capped by two compact domains at the N- and
C-termini. Fig. 3 shows the tetrameric assembly predicted by the
PISA quaternary-structure tool (Krissinel & Henrick, 2007),
including the malonate ligand in the active site.
Structure alignment of the R. prowazekii FumC monomer with
the human enzyme using MultiProt (Shatsky et al., 2004) showed an
r.m.s.d. of 0.99 A ˚ over 92% of the sequence. The average C
  r.m.s.d.
of a global alignment of FumC structures from Rickettsia (bound to
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Figure 3
Two views of the tetrameric assembly predicted by PISA from the 3gtd coordinates
(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html) showing the schematic back-
bone trace of the four subunits modelled for dimer 1 chain A (blue) and B (yellow)
and dimer 2 chain A (magenta) and B (green). (a) The side view of each chain
bound to the ligand malonate shown in CPK. (b) The two sodium ions at the
interface of each dimer can be seen near the central axis of symmetry.
Table 1
Data-collection statistics.
Values in parentheses are for the highest of 20 resolution shells.
Space group P3121
Unit-cell parameters (A ˚ ) a = b = 144.9, c = 106.21
Wavelength (A ˚ )1 . 0
Resolution range (A ˚ ) 19.74–2.4 (2.46–2.40)
No. of unique reﬂections 46831
Completeness (%) 99.7 (97.5)
Rmerge† 0.12 (0.73)
Mean I/ (I) 9.5 (2.7)
†
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.
Table 2
Reﬁnement and model statistics.
Values in parentheses are for the highest of 20 resolution shells.
Resolution range (A ˚ ) 19.74–2.4 (2.46–2.40)
Rcryst† 0.194
Rfree† 0.226
R.m.s.d. bonds (A ˚ ) 0.0080
R.m.s.d. angles ( ) 1.043
Protein atoms 6571
Nonprotein atoms 213
Mean B factor (A ˚ 2) 20.275
Residues in favored region (%) 98
Residues in allowed region (%) 100
MolProbity‡ score [percentile] 1.4 [99th]
† Rcryst =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj. The free R factor was calculated using 5% of
the reﬂections omitted from the reﬁnement (Winn et al., 2011). ‡ Chen et al. (2010).
Table 3
Best pairwise backbone C
  r.m.s.d. between the FumC structure from Rickettsia
and those from human, E. coli and S. cerevisiae (yeast) calculated using MultiProt
(Shatsky et al., 2004).
Structure pairs R.m.s.d. (A ˚ ) Alignment size (residues)
3gtd (Rickettsia)/1kq7 (E. coli) 0.98 416
3gtd (Rickettsia)/1yfm (yeast) 0.98 418
3gtd (Rickettsia)/3e04 (human) 0.99 423the product analog malonate in the active site), human (unbound;
PDB entry 3e04; Structural Genomics Consortium, unpublished
work), E. coli (bound to the competitive inhibitor citrate in the active
site and to S-malate in the B site; Este ´vez et al., 2002) and Saccharo-
myces cerevisiae (unbound; Weaver et al., 1998) is 0.90 A ˚ over 410
residues (see Table 3 for pairwise r.m.s.d.s). The largest deviation is
found in the C-terminal region; otherwise the backbone structure is
remarkably conserved, including the active site (see Fig. 4). The
residues located within 6 A ˚ of the ligand in the Rickettsia structure,
Thr96, Ser98, Ser139, Ser140, Asn141, Ala231 and Leu358, are 100%
conserved in the three other species and adopt almost identical
conformations, even in the unbound structures: the r.m.s.d. for all
atoms over those eight residues is 0.83 A ˚ from the human structure,
1.09 A ˚ from that from E. coli and 1.15 A ˚ from that from S. cerevisiae.
The only visible difference between the human and Rickettsia pockets
is the tilting of the Ser140 hydroxyl group away from the active site in
the human structure (see Fig. 5).
FumC displays some essential features of a good drug target: it is
clearly involved in a crucial biological pathway, is functionally well
characterized and possesses a druggable binding site. However, the
structural evidence obtained in the present study strongly indicates
that this enzyme is an unsuitable target for therapeutic intervention
against Rickettsia owing to the very high degree of conservation
between the human and R. prowazekii structures in terms of both the
global fold and the binding site.
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